Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03155867 · ClinicalTrials.gov registry record · NA
Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus
A NA study, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03155867: Completed NA study, sponsored by Société des Produits Nestlé (SPN).
NCT03155867 is a NA study that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03155867, a NA study, has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This will be a randomized, cross-over design. Subjects will be randomized to one of six interventions on six separate study days, 1 week apart.
Interventions
- OTHER Meal replacement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2017-05-18 |
| Phase | NA |
What the finished NCT03155867 record still lists
NCT03155867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Meal replacement is the first listed.
NCT03155867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03155867 about?
NCT03155867 is a clinical study titled "Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus". This will be a randomized, cross-over design. Subjects will be randomized to one of six interventions on six separate study days, 1 week apart.
What is the current status of trial NCT03155867?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2017-04-05. Estimated completion is 2017-05-18.
What interventions are being tested in trial NCT03155867?
The interventions under investigation include: Meal replacement (OTHER).
Who is sponsoring clinical trial NCT03155867?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03155867's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI